Measurement of 5-methoxypsoralen and 8-methoxypsoralen in saliva of PUVA patients as a noninvasive, clinically relevant alternative to monitoring in blood

Archives of Dermatological Research

Volumn 291, Issue 9, 1999, Pages 491-499

  Shephard, Sarah E ^a   Zogg, Marianne ^a   Burg, Günter ^a   Panizzon, Renato G ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Albumin binding; Analysis; Nonresponder; Pharmacokinetics

Indexed keywords

BERGAPTEN; METHOXSALEN; PHOTOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; PUVA; SALIVA; SEZARY SYNDROME;

ADULT; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; METHOXSALEN; MIDDLE AGED; OSMOLAR CONCENTRATION; PUVA THERAPY; REFERENCE VALUES; SALIVA; SEZARY SYNDROME; TIME FACTORS;

EID: 0032842351     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004030050443     Document Type: Article

References (35)

1. Momtaz K, Fitzpatrick TB (1988) The benefits and risks of long-term PUVA photochemotherapy. Dermatol Clin 16: 227-234
2. Lauharanta J (1997) Photochemotherapy. Clin Dermatol 15: 769-780
3. British Photodermatology Group (1994) Guidelines for PUVA. Br J Dermatol 130: 246-255
4. Herfst MJ, Wolff FA de (1983) Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients. Clin Pharmacol Ther 34: 117-124
5. Bonnot D, Béani JC, Bourrain JL, Berthod F, Boitard M, Reymond JL, Bériel H, Amblard P (1994) Analysis of 8-methoxypsoralen plasma kinetics in 475 subjects: investigation of factors that could modify the bioavailability of 8-MOP. J Dermatol Treat 5: 71-75
6. Schafer-Korting M, Korting HC (1982) Intraindividual variations of methoxypsoralen plasma levels. Arch Dermatol Res 272: 1-7
7. Bonnot D, Béani J, Boitard M, Reymond J, Bériel H, Amblard P (1994) Determination of 8-methoxypsoralen kinetics: a relevant factor in the treatment of psoriasis by psoralen plus ultraviolet A therapy. Photodermatol Photoimmunol Photomed 10: 33-37
8. Reymond J, Béani J, Racinet H, Bonnot D, Bériel H, Amblard P (1988) Comparative pharmacokinetics of 8-MOP in serum and in suction blister fluid. Photodermatology 5: 51-52
9. Wolff FA de, Thomas TV (1986) Clinical pharmacokinetics of methoxsalen and other psoralens. Clin Pharmacokinet 11: 62-75
10. Korting HC, Schäfer-Korting M, Roser-Maass E, Mutschier E (1982) Determination of 8-methoxypsoralen levels in plasma and skin suction blister fluid by a new sensitive fluorodensitometric method. Arch Dermatol Res 272: 9-20
11. Hönigsmann H, Jaschke E, Nitsche V, Brenner W, Rauschmeier W, Wolff K (1982) Serum levels of 8-methoxypsoralen in two different drug preparations: correlation with photosensitivity and UVA dose requirements for photochemotherapy. J Invest Dermatol 79: 233-236
12. Mclelland J, Fisher C, Fair P, Diffey B, Cox N (1991) The relationship between plasma psoralen concentration and psoralen-UVA erythema. Br J Dermatol 124: 585-590
13. Carter DM, Goldslein DP (1984) Quantitative tests for psoralens in the blood: methods and uses in monitoring psoralen and longwave radiation therapy. Natl Cancer Inst Monogr 66: 69-72
14. Schmid J, Prox A, Reuter A, Zipp H, Koss FW (1980) The metabolism of 8-methoxypsoralen in man. Eur J Drug Metab Pharm 5: 81-92
15. Brickl R, Schmid J, Koss FW (1984) Clinical pharmacology of oral psoralen drugs. Photodermatology 1: 174-186
16. Stolk L, Siddiqui AH, Kammeyer A, Cormane RH, Van Zwieten PA (1981) Serum and saliva levels of 8-methoxypsoralen after rectal administration as a micro-enema. Br J Dermatol 104: 447-451
17. Herfst MJ, Wolff FA de (1982) Influence of food on the kinetics of 8-methoxypsoralen in serum and suction blister fluid in psoriatic patients. Eur J Clin Pharmacol 23: 75-80
18. Karolak L, Tod M, Leon A, Heudes A, Petitjean O, Laroche L (1992) In vitro kinetics of 8-methoxypsoralen penetration into human lymphoid cells. Photodermatol Photoimmunol Photomed 9: 58-60
19. Mays D, Rogers S, Guiler R, Sharp D, Hecht S, Staubus A, Gerber N (1986) Disposition of 8-methoxypsoralen in the rat: methodology for measurement, dose-dependent pharmacokinetics, tissue distribution and identification of metabolites. J Pharmacol Exp Ther 236: 3364-3373
20. Warner W, Giles A, Kernhauser A (1987) Kinetics of 8-methoxypsoralen and 5-methoxypsoralen distribution in guinea pig serum, epidermis and ocular lens. Photodermatology 4: 236-239
21. Monbaliu J, Belpaire F, Bogaert M (1988) Study of the bioavailability of different formulations of 8-methoxypsoralen in the dog. Biopharm Drug Dispos 9: 1-8
22. Schäfer-Korung M (1985) Penetration von 8-Methoxypsoralen in die Saugblasenflüssigkeit bei Ratten. Arch Pharm (Weinheim) 318: 720-726
23. Lauharanta J, Juvakoski T, Kanerva L, Lassus A (1982) Pharmacokinetics of 8-methoxypsoralen in serum and suction blister fluid. Arch Dermatol Res 273: 111-114
24. Humbert P, Treffel P, Makki S, Millet J, Agache P (1991) Peak blistering point: influence on fluid levels of 5-MOP in human skin in vivo after systemic administration. Arch Dermatol Res 283: 297-299
25. Rowland M, Tozer N (1989) Clinical pharmacokinetics. Concepts and applications, 2nd edn. Lea & Febriger, Philadelphia, p 111
26. Vermeer B, Reman F, Gent C van (1979) The determination of lipids and proteins in suction blister fluid. J Invest Dermatol 73: 303-305
27. Derendorf H, Garrett E (1987) Pharmakokinetik. Einführung in die Theorie und Relevanz für die Arzneimitteltherapie. Wissenschaftliche Verlagsgesellschaft, Stuttgart
28. Muret P, Makki S, Urien S, Humbert P, Bechtel P, Tillement JP, Agache P (1993) 5-methoxypsoralen binding to proteins: influence of drugs used in PUVA therapy. Eur J Dermatol 4: 322-323
29. Pibouin M, Zini R, Nguyen P, Renouant A, Tillement JP (1987) Binding of 8-methoxypsoralen to human serum proteins and red blood cells. Br J Dermatol 111: 207-215
30. Veronese F, Bevilacqua R, Schiavon O, Rodighiero G (1979) Drug-protein interaction: plasma protein binding of furo-coumarins. Farmaco Edizione Sci 34: 716-725
31. Busch U, Schmid J, Koss F, Zipp H, Zimmer A (1978) Pharmacokinetics and metabolite-pattern of 8-methoxypsoralen in man following oral administration as compared to the pharmacokinetics in rat and dog. Arch Dermatol Res 262: 255-265
32. Artuc M, Stuettgen G, Schalla W, Schaefer H, Gazith J (1979) Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro. Br J Dermatol 101: 669-677
33. Muret P, Humbert P, Makki S, Bechtel P, Urien S, Tillement JP (1993) Serum free 5-methoxypsoralen fraction in health and psoriasis: relationship with human serum albumin concentration. Arch Dermatol Res 285: 287-290
34. Muret P, Makki S, Urien S, Agache P, Bechtel P, Tillement J-P (1993) Binding of 5-methoxypsoralen to blood fractions. Skin Pharmacol 6: 45-51
35. Shephard SE, Nestle FO, Panizzon R (1999) Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis. Photodermatol Photoimmunol Photomed 15:64-74